Insider Trading March 16, 2026

Myomo Director Adds to Stake as Shares Trade Near 52-Week Low

Kirk Thomas F buys 72,000 shares; company posts Q4 revenue beat and expands insurance coverage while executive pay is partially converted to equity

By Jordan Park MYO
Myomo Director Adds to Stake as Shares Trade Near 52-Week Low
MYO

Myomo director Kirk Thomas F purchased 72,000 common shares on March 13, 2026, in a trade valued at $51,112. The buy comes as the stock trades close to its 52-week low after a steep decline over the past year. Separately, the company reported better-than-expected fourth-quarter revenue and completed network participation agreements with Elevance Health, while its CEO and CFO accepted salary reductions in exchange for restricted stock units.

Key Points

  • Director Kirk Thomas F bought 72,000 Myomo shares on March 13, 2026, for $51,112 at a weighted average price of $0.7099; he now directly owns 553,857 shares.
  • Myomo reported Q4 revenue of $11.4 million, above the $10.4 million consensus, and an adjusted EBITDA loss of $1.9 million versus an expected -$3.0 million.
  • The company signed network participation agreements with Elevance Health potentially adding 45 million members and bringing commercial covered lives to over 80 million; Craig-Hallum cut its price target to $1.10 from $2.00.
  • CEO Paul Gudonis and CFO David Henry will accept 10% base salary reductions for 2026 in exchange for RSUs valued at 115% of the foregone salary, approved by the Compensation Committee.

Director Kirk Thomas F increased his direct ownership in Myomo, Inc. (NYSE: MYO) by purchasing 72,000 common shares on March 13, 2026. The transaction carried a total value of $51,112, with execution prices between $0.70 and $0.71 and a weighted average price of $0.7099. Following this purchase, Kirk directly owns 553,857 shares of the company.

The insider purchase takes place against a challenging market backdrop for the stock. MYO has fallen roughly 86% over the last 12 months and is trading near its 52-week low of $0.63. According to InvestingPro analysis cited by the company, the shares appear undervalued relative to Fair Value metrics, and additional proprietary research on MYO is available through the platform's Pro Research Report covering more than 1,400 U.S. equities.

Operationally, Myomo reported fourth-quarter revenue of $11.4 million, topping the Street estimate of $10.4 million. The company posted an adjusted EBITDA loss of $1.9 million, which was narrower than the consensus expectation of a negative $3.0 million. Those results present a mixed picture: revenue exceeded analyst forecasts while the business remains unprofitable on an adjusted EBITDA basis.

Despite the revenue beat and improved adjusted EBITDA relative to expectations, Craig-Hallum reduced its price target on Myomo to $1.10 from $2.00. The firm cited the combination of mixed quarterly results and fiscal 2026 guidance that fell short of Wall Street projections as the rationale for the lower target.

On the commercial access front, Myomo has executed network participation agreements with Elevance Health. The agreements will extend coverage across Anthem-affiliated Commercial, Medicare Advantage, and Medicaid plans and could add as many as 45 million medical members to the company’s potential coverage by the second quarter of 2026. Including this expansion, Myomo expects to have more than 80 million covered lives under commercial insurance plans.

Management also elected a change in compensation structure for 2026. CEO Paul Gudonis and CFO David Henry have agreed to reduce their base salaries by 10% for 2026 in exchange for restricted stock units. The company’s Compensation Committee approved a program under which the executives will receive RSUs valued at 115% of the salary amounts they forego. The company described these moves as part of efforts to align executive compensation with company performance.

Taken together, the insider purchase, the quarterly results, the expanded insurance network, and the executive compensation changes represent a cluster of developments that stakeholders will monitor for their implications on Myomo’s commercial reach and financial trajectory. The mix of a revenue beat alongside continued adjusted EBITDA losses and a lower analyst price target underscores the uncertain path to sustained profitability.


Sectors affected: Healthcare services and small-cap equity markets.

Risks

  • Equity risk: MYO shares have declined approximately 86% over the past year and are trading near a 52-week low of $0.63, indicating elevated market risk for shareholders.
  • Profitability and guidance risk: The company reported an adjusted EBITDA loss and Craig-Hallum cited fiscal 2026 guidance that failed to meet Wall Street expectations when lowering its price target.
  • Execution and reimbursement risk: Expansion into Elevance Health networks could take time to translate into revenue, creating uncertainty for near-term commercial uptake and reimbursement realization.

More from Insider Trading

Dolphin CEO William O’Dowd Buys 3,100 Shares as Company Highlights Organic Growth Mar 16, 2026 Climb Global CEO Sells $684K in Shares as Stock Trades Near Yearly Low Mar 16, 2026 Montrose Environmental CEO offloads shares while exercising options; company posts quarterly beat Mar 16, 2026 Accel Entertainment Director Rubenstein Disposes $2.01M in Class A-1 Shares Mar 16, 2026 Sprouts CTO Disposes Small Stake as Analysts Trim Targets Mar 16, 2026